Renhe Pharmaceutical: Subsidiary product ULoox brain-computer interaction intelligent glasses have no income yet.

Renhe Pharmaceutical announced that the closing prices of the company's stock on August 20 and August 21, 2025, consecutively deviated by over 20.42%, indicating abnormal fluctuations in stock trading. Upon verification, there is no need to correct or supplement the information disclosed by the company earlier. The recent operational situation is normal, and there have been no significant changes in the internal and external environment. The controlling shareholder and actual controller have no undisclosed significant matters to disclose, and they did not buy or sell company stocks during the abnormal fluctuation period. The subsidiary's ULoox brain-computer interactive smart glasses have only produced samples and have not generated any sales revenue, which does not have a significant impact on the current performance.